Recombinant PDCD1 (Pembrolizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all PDCD1 (Pembrolizumab Biosimilar) products
- PDCD1 (Pembrolizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Mammalian Cells
- Expression System
- Mammalian cells
-
Clonality
- Monoclonal
-
Conjugate
- This PDCD1 (Pembrolizumab Biosimilar) antibody is un-conjugated
-
Application
- ELISA
- Purpose
- Pembrolizumab Biosimilar - Anti-PD1 mAb
- Characteristics
- Antibody Type: IgG4
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Grade
- Research Grade
- Isotype
- IgG4
-
anti-PDCD1 (Pembrolizumab Biosimilar) antibody
Research Grade Reactivity: Human FACS, ELISA Host: Humanized Monoclonal unconjugated Recombinant Antibody
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- 4 °C,-20 °C
- Storage Comment
- 4°C for short term, -20°C for long term
-
- Target
- PDCD1 (Pembrolizumab Biosimilar)
- Abstract
- PDCD1 (Pembrolizumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
-
Pembrolizumab
Pembrolizumab is a humanized (from mouse) monoclonal antibody that binds to, and blocks PD-1 located on lymphocytes. It is an anticancer medication used in the treatment of melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer (cancer of the bladder and urinary tract) and renal cell carcinoma (kidney cancer).
-
You are here:
